US5336489A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1992-02-27
•
Granted: 1994-08-09
•
Expires: 2012-02-27
Abstract
Abstract A method of lysing unwanted, non-malignant cells in a mammal, the cells having on their surfaces a receptor for a growth factor, and the method including administering to the mammal a cell-lysing amount of a substance characterized in that it has specific affinity for the receptor of the growth factor and has the ability to effect the lysis of the cells.
Inventors
- 👤 Terry B. Strom
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:15
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2866; A; A61; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61K; A61K39/00; A61K2039/505; A61K38/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
72 words
A method of inhibiting the T-lymphocyte induced rejection of an allograft in a mammal, said T-lymphocytes, in connection with said allograft rejection, undergoing a proliferative burst characterized by the presence of IL-2 receptors on the surface of said T-lymphocytes, said method comprising administering to said mammal, following said allograft, and during said proliferative burst, a cytotoxin linked to an IL-2 receptor-specific substance, which substance has a specific affinity for the IL-2 receptor.
Claim 2
Independent Claim
72 words
A method of inhibiting the T-lymphocyte induced rejection of an allograft in a mammal, said T-lymphocytes, in connection with said allograft rejection, undergoing a proliferative burst characterized by the presence of IL-2 receptors on the surface of said T-lymphocytes, said method comprising administering to said mammal, following said allograft, and during said proliferative burst, a cytotoxin linked to an IL-2 receptor-specific substance, which substance has a specific affinity for the IL-2 receptor.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein said cytotoxin is a toxin.
Claim 4
Dependent Claim
11 words
The method of claim 2, wherein said toxin is diphtheria toxin.
Claim 5
Dependent Claim
10 words
The method of claim 2, wherein said toxin is ricin.
Claim 6
Independent Claim
15 words
The method of any one of claims 1-4, wherein said IL-2 receptor-specific substance is IL-2.
Claim 7
Independent Claim
16 words
The method of any one of claims 1-4, wherein said IL-2 receptor-specific substance is an antibody.
References Cited (Backward Citations)
US4440747A
Cited
US4388309A
Cited
EP0091539A1
Cited
US4675382A
Cited
EP0118977A1
Cited
EP0119621A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-08-08 | 1998-02-07 | 1998-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-08-08 | 2002-02-07 | 2002-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-08-08 | 2006-02-07 | 2006-08-09 | $7700.00 | Window Closed / Lapsed |